| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
09-01-2017, 01:17 AM
|
#7 | ||
|
|||
|
Senior Member
|
My thanks go to NewsBot for pointing me to this:
Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long-acting version of generic - MarketWatch "Gocovri is a new formulation of amantadine, at a new price: between $10,000 and $30,000 a year." '... Chief Executive Greg Went and Chief Medical Officer Rajiv Patni emphasized that there are other important differences. Gocovri is “not a convenience play” but rather a new chemical entity that is designed to be more effective, they said; moreover, the product represents 13 years and “well over” $100 million in investment.' For sure there is a different release mechanism, but does anyone know how Gocovri differs chemically from amantadine? John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
|
 Reply With Quote
|
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Deanol in the treatment of levodopa‐induced dyskinesias | Parkinson's Disease | |||
| Addex begins phase IIa trial of dipraglurant in Parkinson's disease levodopa-induced | Parkinson's Disease | |||
| Levodopa Induced Dyskinesia? | Parkinson's Disease | |||
| ..all doses of ADX10059 abolished levodopa induced dyskinesia... | Parkinson's Disease | |||
| Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease | Parkinson's Disease | |||
Threaded Mode